Syros Pharmaceuticals Projected to Post Quarterly Earnings

The biotech company is expected to report earnings on Wednesday, March 25th.

Mar. 23, 2026 at 7:05am

Got story updates? Submit your updates here. ›

Syros Pharmaceuticals (NASDAQ:SYRS), a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is anticipated to release its quarterly earnings results on Wednesday, March 25th. Analysts expect the company to post earnings of ($0.1580) per share for the quarter.

Why it matters

As a publicly traded biotech firm, Syros Pharmaceuticals' quarterly earnings reports are closely watched by investors to gauge the company's financial performance and progress in developing its pipeline of targeted therapeutics.

The details

Syros Pharmaceuticals is pioneering a new class of targeted therapies by focusing on the control of gene expression. The company's lead development candidate, tamibarotene (SY-1425), is an oral, selective RARα agonist being evaluated in acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

  • Syros Pharmaceuticals is anticipated to release its quarterly earnings results on Wednesday, March 25th.

The players

Syros Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that is pioneering a new class of targeted therapeutics by focusing on the control of gene expression.

Got photos? Submit your photos here. ›

The takeaway

Syros Pharmaceuticals' upcoming earnings report will provide investors with an update on the company's financial performance and progress in advancing its pipeline of targeted gene control therapies for cancer and rare genetic disorders.